ClinicalTrials.gg

Poliomyelitis clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 274 studies for Poliomyelitis across more than 10 countries. 18 are recruiting or about to start. 145 of them are mainly about Poliomyelitis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its narrower condition Postpoliomyelitis Syndrome too: 295 studies, 21 open.

Status

Completed
224
Status unknown
16
Recruiting
11
Not yet recruiting
7
Active, not recruiting
7
Terminated
5

Phase

Phase 3
104
Phase 4
61
Phase 2
46
Phase 1
24

Where

China
49
Bangladesh
23
United States
21
Pakistan
12
Germany
11
France
11

Who develops what

Add Poliomyelitis to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 9 programs from 5 companies, 6 with this as their studies’ main aim; 2 with a live phase 3 study; 1 primary completion in the next 12 months. Compare Sinovac Biotech, Serum Institute of India Pvt. and LG Chem here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis -Haemophilus influenzae type b conjugate vaccineRecent, limited
Evidence
  • NCT07354269 · Sinovac Biotech Co., Ltd · Phase 4 · live · comparator · “DTaP-IPV-Hib” · registered Apr 2025
GlaxoSmithKline64% of its industry studies11 study
13-valent pneumococcal vaccineEarlier onlyPhase 4 trial recorded
Evidence
  • NCT04398706 · Sanofi · Phase 2 · comparator · “Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]” · registered May 2020
  • NCT02422264 · GlaxoSmithKline · Phase 4 · background · “Prevnar13” · registered Mar 2015
  • NCT02096263 · GlaxoSmithKline · Phase 3 · background · “Prevnar13” · registered Mar 2014
  • NCT01480258 · MCM Vaccines B.V. · Phase 3 · background · “Prevenar 13™” · registered Nov 2011
  • NCT01453998 · GlaxoSmithKline · Phase 2 · background · “Prevenar 13” · registered Oct 2011
Pfizer73% of its industry studies00 studies
Diphtheria-Tetanus-acellular Pertussis VaccinesEarlier only
Evidence
  • NCT01337167 · Merck & Co., Inc · Phase 3 · background · “DAPTACEL™” · registered Apr 2011
  • NCT01323647 · GlaxoSmithKline · Phase 3 · background · “Infanrix+Hib” · registered Mar 2011
  • NCT00319852 · Sanofi · Phase 3 · comparator · “DTaP vaccine” · registered Apr 2006
  • NCT00287092 · Sanofi · Phase 3 · comparator · “Infanrix® -IPV+Hib” · registered Feb 2006
—00 studies

3 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 9 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Oct 2027 est.Vaccines, Combined · Serum Institute of India Pvt. Ltd. · Phase 2 named, not the main aimNCT07855172 Safety and Immunogenicity of a Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Recombinant Poliomyelitis and Haemophilus Influenzae Type b (Hib) Vaccine (SIIPL DTwP-HepB-rPV-Hib) — primary endpoint: The incidence, severity and relationship of solicited AEs occurring up to 7 days following vaccination, unsolicited AEs and Serious Adverse Events till 28 days following vaccination in toddlers · 186 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Poliomyelitis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Coming up

8studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 8, phase 3 first

Who these studies take

Of the 11 Poliomyelitis studies recruiting now, 0 (0%) set no upper age limit and 11 (100%) stop at 75 or younger. 10 (91%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 11 (100%) take healthy volunteers.

Recruiting studies that take each age, of 11
AgeWomenMen
102 (18%)2 (18%)
183 (27%)3 (27%)
303 (27%)3 (27%)
403 (27%)3 (27%)
502 (18%)2 (18%)
650 (0%)0 (0%)
750 (0%)0 (0%)
850 (0%)0 (0%)

Across all 274 studies, recruiting or not: 91% stop at 75 or younger and 90% at 65; 87% take children; 1% are for women only and 1% for men only; 91% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Poliomyelitis studies take

Of 45 phase 3 interventional studies under Poliomyelitis, half reached primary completion within 12 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 13 mo2–18 · 12 studies——
Phase 212 mo5–38 · 12 studies——
Phase 312 mo7–21 · 45 studies15 mo7–21 · 36 studies—
Phase 413 mo7–25 · 30 studies——
Interventional, no phase19 mo12–22 · 16 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 274. Browse all 274 → or search them.